Phytochemicals approach for Developing cancer immunotherapeutics

Shu Yi Yin, Ning Sun Yang, Tien-Jen Lin

Research output: Contribution to journalShort survey

8 Citations (Scopus)

Abstract

Phytochemicals or their derived compounds are being increasingly recognized as potentially potent complementary treatments for cancer. Among them, some phytochemicals are being actively evaluated for use as adjuvants in anticancer therapies. For instance, shikonin and hypericin were found to induce immunogenic cell death of specific cancer cells, and this effect was able to further activate the recognition activity of tumor cells by the host immune system. On the other hand, some derivatives of phytochemicals, such as dihydrobenzofuran lignan (Q2-3) have been found to induce the secretion of an endogenous anticancer factor, namely IL-25, from non-malignant cells. These findings suggest that phytochemicals or their derivatives confer a spectrum of different pharmacological activities, which contrasts with the current cytotoxic anticancer drugs commonly used in clinics. In this review, we have collected together pertinent information from recent studies about the biochemical and cellular mechanisms through which specific phytochemicals regulate target immune systems in defined tumor microenvironments. We have further highlighted the potential application of these immunotherapeutic modifiers in cell-based cancer vaccine systems. This knowledge provides useful technological support and know how for future applications of phytochemicals in cancer immunotherapy.

Original languageEnglish
Article number386
JournalFrontiers in Pharmacology
Volume8
Issue numberJUN
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Phytochemicals
Neoplasms
Immune System
Lignans
Cancer Vaccines
Tumor Microenvironment
Immunotherapy
Cell Death
Pharmacology
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cancer immunotherapy
  • Herbal extract
  • Phytochemicals
  • Tumor microenvironment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Phytochemicals approach for Developing cancer immunotherapeutics. / Yin, Shu Yi; Yang, Ning Sun; Lin, Tien-Jen.

In: Frontiers in Pharmacology, Vol. 8, No. JUN, 386, 01.01.2017.

Research output: Contribution to journalShort survey

@article{ab433a22ea3c478ebed8838f9d90c493,
title = "Phytochemicals approach for Developing cancer immunotherapeutics",
abstract = "Phytochemicals or their derived compounds are being increasingly recognized as potentially potent complementary treatments for cancer. Among them, some phytochemicals are being actively evaluated for use as adjuvants in anticancer therapies. For instance, shikonin and hypericin were found to induce immunogenic cell death of specific cancer cells, and this effect was able to further activate the recognition activity of tumor cells by the host immune system. On the other hand, some derivatives of phytochemicals, such as dihydrobenzofuran lignan (Q2-3) have been found to induce the secretion of an endogenous anticancer factor, namely IL-25, from non-malignant cells. These findings suggest that phytochemicals or their derivatives confer a spectrum of different pharmacological activities, which contrasts with the current cytotoxic anticancer drugs commonly used in clinics. In this review, we have collected together pertinent information from recent studies about the biochemical and cellular mechanisms through which specific phytochemicals regulate target immune systems in defined tumor microenvironments. We have further highlighted the potential application of these immunotherapeutic modifiers in cell-based cancer vaccine systems. This knowledge provides useful technological support and know how for future applications of phytochemicals in cancer immunotherapy.",
keywords = "Cancer immunotherapy, Herbal extract, Phytochemicals, Tumor microenvironment",
author = "Yin, {Shu Yi} and Yang, {Ning Sun} and Tien-Jen Lin",
year = "2017",
month = "1",
day = "1",
doi = "10.3389/fphar.2017.00386",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Phytochemicals approach for Developing cancer immunotherapeutics

AU - Yin, Shu Yi

AU - Yang, Ning Sun

AU - Lin, Tien-Jen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Phytochemicals or their derived compounds are being increasingly recognized as potentially potent complementary treatments for cancer. Among them, some phytochemicals are being actively evaluated for use as adjuvants in anticancer therapies. For instance, shikonin and hypericin were found to induce immunogenic cell death of specific cancer cells, and this effect was able to further activate the recognition activity of tumor cells by the host immune system. On the other hand, some derivatives of phytochemicals, such as dihydrobenzofuran lignan (Q2-3) have been found to induce the secretion of an endogenous anticancer factor, namely IL-25, from non-malignant cells. These findings suggest that phytochemicals or their derivatives confer a spectrum of different pharmacological activities, which contrasts with the current cytotoxic anticancer drugs commonly used in clinics. In this review, we have collected together pertinent information from recent studies about the biochemical and cellular mechanisms through which specific phytochemicals regulate target immune systems in defined tumor microenvironments. We have further highlighted the potential application of these immunotherapeutic modifiers in cell-based cancer vaccine systems. This knowledge provides useful technological support and know how for future applications of phytochemicals in cancer immunotherapy.

AB - Phytochemicals or their derived compounds are being increasingly recognized as potentially potent complementary treatments for cancer. Among them, some phytochemicals are being actively evaluated for use as adjuvants in anticancer therapies. For instance, shikonin and hypericin were found to induce immunogenic cell death of specific cancer cells, and this effect was able to further activate the recognition activity of tumor cells by the host immune system. On the other hand, some derivatives of phytochemicals, such as dihydrobenzofuran lignan (Q2-3) have been found to induce the secretion of an endogenous anticancer factor, namely IL-25, from non-malignant cells. These findings suggest that phytochemicals or their derivatives confer a spectrum of different pharmacological activities, which contrasts with the current cytotoxic anticancer drugs commonly used in clinics. In this review, we have collected together pertinent information from recent studies about the biochemical and cellular mechanisms through which specific phytochemicals regulate target immune systems in defined tumor microenvironments. We have further highlighted the potential application of these immunotherapeutic modifiers in cell-based cancer vaccine systems. This knowledge provides useful technological support and know how for future applications of phytochemicals in cancer immunotherapy.

KW - Cancer immunotherapy

KW - Herbal extract

KW - Phytochemicals

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85020845262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020845262&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00386

DO - 10.3389/fphar.2017.00386

M3 - Short survey

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUN

M1 - 386

ER -